Becton, Dickinson and Company
BDX Healthcare Medical Instruments & Supplies
- Revenue
- −10.5%
- EPS
- +48.5%
- Free cash flow
- −31.6%
- Total debt
- −23.8%
Quarter to September 2026, against a year earlier
Follow BDX
Alert me
Becton, Dickinson and Company 10-K filed Nov 25, 2025
What changed
Item 1, Business, against the 10-K filed Nov 27, 2024: 7 added · 12 removed · 33 modified; 2 with only figures updated
-
Modified · Business Segments
As of September 30, 2025, BD’s operations
consistconsisted of three worldwide business segments: BD Medical, BD Life Sciences and BD Interventional. Asisfurtherdescribed below, on September 3, 2024, BD completed its acquisition of Edwards Lifesciences’ Critical Care product group (“Critical Care”)discussed in Note 8 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data,which was renamed aseffective October 1, 2025, BDAdvanced Patient Monitoring (“Advanced Patient Monitoring”) and operates as a separate organizational unit within the Company’s Medical segmentreorganized its organizational units into five distinct, separately-managed segments, based on the nature of BD’s product and service offerings.Information with respect to BD’s businessBD’s new organizational structure is based upon the following five segmentsis included in Notes 8: Medical Essentials, Connected Care, BioPharma Systems,11Interventional and16, respectivelyLife Sciences,to the consolidated financial statements contained in Item 8. Financial Statementswhich remains a critical part of BD until the separation and combination of our Biosciences andSupplementary DataDiagnostic Solutions business with Waters Corporation (“Waters”),and is incorporated herein by referenceas further discussed below, is completed.